← Back to patent-cliff list
NIO-752
Tier C — Watch / tradeNIO-752
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：TAU
Indications (approved)：进行性核上性麻痹, Neurodegenerative disease, Alzheimer's disease, Mild cognitive impairment
Regional status
US
Phase III
2026-06-03
EU
Phase III
2026-06-03
China
Phase III
2026-06-03
Japan
Phase III
2026-06-03
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NIO-752?
Approved indications include: 进行性核上性麻痹, Neurodegenerative disease, Alzheimer's disease, Mild cognitive impairment.
When does the NIO-752 patent expire?
No public expiry year is available for NIO-752 yet; this page updates once verified.
How do I get a quote for NIO-752 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29